Orion Oyj/€ORNBV
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Orion Oyj
Orion Oyj is a Finnish pharmaceutical and diagnostics company engaged primarily in the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. It operates through two main segments: the Pharmaceuticals segment, which includes proprietary drugs, specialty products, and animal health, and the Diagnostics segment, which comprises the Orion Diagnostica company focused on diagnostic tests. Founded in 1917, Orion is headquartered in Espoo, Finland, and operates globally with a significant presence in the Nordic countries and significant partnerships worldwide. Orion's strategic focus includes a strong emphasis on its proprietary drug portfolio, particularly in the central nervous system and oncology sectors, which constitutes a crucial component of its competitive strengths.
Ticker
€ORNBV
Sector
Primary listing
XHEL
Employees
3,700
Headquarters
Espo, Finland
Website
Orion Oyj Metrics
BasicAdvanced
€9.5B
25.37
€2.69
0.38
€1.63
2.39%
Price and volume
Market cap
€9.5B
Beta
0.38
52-week high
€71.60
52-week low
€40.78
Average daily volume
83K
Dividend rate
€1.63
Financial strength
Current ratio
1.863
Quick ratio
1.046
Long term debt to equity
14.789
Total debt to equity
34.569
Dividend payout ratio (TTM)
60.63%
Interest coverage (TTM)
54.15%
Profitability
EBITDA (TTM)
482.1
Gross margin (TTM)
61.84%
Net profit margin (TTM)
22.54%
Operating margin (TTM)
25.84%
Effective tax rate (TTM)
20.15%
Revenue per employee (TTM)
€450,000
Management effectiveness
Return on assets (TTM)
17.45%
Return on equity (TTM)
44.96%
Valuation
Price to earnings (TTM)
25.372
Price to revenue (TTM)
5.72
Price to book
10.38
Price to tangible book (TTM)
13.01
Price to free cash flow (TTM)
43.993
Free cash flow yield (TTM)
2.27%
Free cash flow per share (TTM)
1.551
Dividend yield (TTM)
2.39%
Growth
Revenue change (TTM)
33.19%
Earnings per share change (TTM)
63.01%
3-year revenue growth (CAGR)
16.09%
10-year revenue growth (CAGR)
5.22%
3-year earnings per share growth (CAGR)
23.29%
10-year earnings per share growth (CAGR)
5.88%
3-year dividend per share growth (CAGR)
3.02%
10-year dividend per share growth (CAGR)
2.35%
Bulls say / Bears say
Orion posted Q1 2025 net sales of €354.6 million, up 14.9%, and operating profit of €77.9 million, up 39.1%, showing robust growth in both revenue and margins.
The company raised its full-year 2025 outlook, projecting net sales of €1,630–€1,730 million and operating profit of €400–€500 million, signaling confidence in ongoing product strength.
Orion secured an exclusive license deal with Criceto for APORON®, a Phase III apomorphine spray targeting Parkinson’s OFF episodes, adding to its Branded Products portfolio and strengthening its late-stage pipeline.
Operating cash flow per share decreased by 29.7% to €0.55 in Q1 2025, indicating possible volatility in cash generation and a dependence on the timing of royalty and milestone payments.
External net sales in the Fermion segment fell as capacity was shifted to internal projects, pointing to increased revenue concentration and potential underuse of API manufacturing resources.
The formal wind-down of the Protein and Antibody Engineering & Characterization unit in Turku after statutory negotiations could disrupt progress in biologics R&D and delay the clinical development of large molecule therapies.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct15
Orion Oyj
DividendEx-dividend
Oct23
Orion Oyj
DividendPayment
€0.82Per share
FAQs
What’s the current market cap for Orion Oyj stock?
Orion Oyj (ORNBV) has a market cap of €9.5B as of September 14, 2025.
What is the P/E ratio for Orion Oyj stock?
The price to earnings (P/E) ratio for Orion Oyj (ORNBV) stock is 25.37 as of September 14, 2025.
Does Orion Oyj stock pay dividends?
Yes, the Orion Oyj (ORNBV) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is €1.63 and the yield is 2.39%. Orion Oyj has a payout ratio of 60.63% on a trailing twelve-month basis.
When is the next Orion Oyj dividend payment date?
The next Orion Oyj (ORNBV) dividend payment is scheduled for October 23, 2025.
What is the beta indicator for Orion Oyj?
Orion Oyj (ORNBV) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.